Latest News About Eli Lilly And Company

Here are the latest publicly reported items on Eli Lilly and Company.

• Lilly is progressing with obesity and diabetes programs, including tirzepatide (Mounjaro/Zepbound) with ongoing regulatory and pricing discussions in multiple markets.[2][5]
• The company announced leadership transitions in 2025 intended to sustain long-term growth and broaden patient access to medicines.[4]
• In 2025 Lilly completed the acquisition of Verve Therapeutics to expand its genetic medicines portfolio, with further Q2 2025 earnings focus and upcoming results communicated in July 2025 press material.[6]

If you’d like, I can pull more focused coverage (e.g., stock market reaction, FDA filing decisions, or regional pricing policy updates) or summarize a specific article with direct quotes.

Citations:

• The latest coverage of Lilly’s obesity/diabetes programs and related regulatory discussions.[2]
• Leadership transitions announced by Lilly in 2025.[4]
• Verve Therapeutics acquisition and 2025 earnings updates.[6]